Utility Estimates for AD in Children

- Of the remaining utility studies, two were specific to AD in children.

Table 4. Utility Estimates for AD in Children

<table>
<thead>
<tr>
<th>Source of utility estimates</th>
<th>Number of children</th>
<th>Standardisation</th>
<th>Measurment Technique</th>
<th>Health State</th>
<th>Utility Estimate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Garside and colleagues5</td>
<td>578</td>
<td>TTO</td>
<td>STAI</td>
<td>Severe AD</td>
<td>0.60</td>
</tr>
<tr>
<td>Ellis and colleagues3</td>
<td>53</td>
<td>TTO</td>
<td>VAS</td>
<td>Severe AD</td>
<td>0.57</td>
</tr>
<tr>
<td>Costello and colleagues15</td>
<td>41</td>
<td>TTO</td>
<td>EQ-5D</td>
<td>Severe AD</td>
<td>0.54</td>
</tr>
</tbody>
</table>

Hydrogen and colleagues2 conducted a cost-effectiveness analysis of tacrolimus ointment versus corticosteroids in patients with moderate to severe AD. Their results showed:

- The efficacy of tacrolimus and corticosteroids was not statistically different.
- The utility estimates were gathered from a US mail survey in Sweden that produced 242 responses.
- The health state described in the survey was based on the definitions of improvement included in the clinical trial. The health states, and corresponding utilities, were as follows:
  - Virtually cleared: 0.78 to 0.84 improvement from baseline.
  - Slight improvement: 0.50 to 0.56 improvement from baseline.
  - Moderate: 0.30 to 0.36 improvement from baseline.
  - Poor: 0.10 to 0.20 improvement from baseline.

Other Findings

- No studies considered whether AD was affecting particularly sensitive parts of the body (e.g., face).
- The location of AD, as well as AD’s effect on sleep, may be important from a quality-of-life standpoint. Two studies8,9 included sleep as a consideration in their AD health state.
- The states states used as the basis for the utility estimation varied greatly across studies. Two only studies mapped utilities to ICA scores10,11, and their methods were unclear.

CONCLUSIONS

- There are several published studies presenting utility estimates in AD. However, they vary greatly in terms of methods employed.
- Economic evaluations in AD, the results of which are sensitive to uncertainty in utility inputs, have relied on various estimates.

REFERENCES

1. Chen SC, Bayoumi AM, Soon SL, Aftergut K, Cruz P, Sexton SA, et al. A catalog of health economic evaluations in AD, the results of which are sensitive to uncertainty in utility inputs, have relied on various estimates.
2. Garside R, Stein K. A cost-utility analysis of pimecrolimus cream 1% versus topical corticosteroids in AD. Health Technology Assessment. 2006. Available at: http://www.valueofhealth.org/background. Accessed Feb 23, 2006. E-mail: dmladsi@rti.org Fax: +1.919.541.7222 Phone: +1.919.541.7094 200 Park Offices Drive RTP Health Solutions, Research Triangle Park, NC, United States

Table 5. Utility Estimates Based on Short-Form Health Surveys

<table>
<thead>
<tr>
<th>Source of utility estimates</th>
<th>Number of children</th>
<th>Standardisation</th>
<th>Measurment Technique</th>
<th>Health State</th>
<th>Utility Estimate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Garside and colleagues5</td>
<td>578</td>
<td>TTO</td>
<td>STAI</td>
<td>Severe AD</td>
<td>0.60</td>
</tr>
<tr>
<td>Ellis and colleagues3</td>
<td>53</td>
<td>TTO</td>
<td>VAS</td>
<td>Severe AD</td>
<td>0.57</td>
</tr>
<tr>
<td>Costello and colleagues15</td>
<td>41</td>
<td>TTO</td>
<td>EQ-5D</td>
<td>Severe AD</td>
<td>0.54</td>
</tr>
</tbody>
</table>

Hydrogen and colleagues2 conducted a cost-effectiveness analysis of tacrolimus ointment versus corticosteroids in patients with moderate to severe AD. Their results showed:

- The efficacy of tacrolimus and corticosteroids was not statistically different.
- The utility estimates were gathered from a US mail survey in Sweden that produced 242 responses.
- The health state described in the survey was based on the definitions of improvement included in the clinical trial. The health states, and corresponding utilities, were as follows:
  - Virtually cleared: 0.78 to 0.84 improvement from baseline.
  - Slight improvement: 0.50 to 0.56 improvement from baseline.
  - Moderate: 0.30 to 0.36 improvement from baseline.
  - Poor: 0.10 to 0.20 improvement from baseline.

Other Findings

- No studies considered whether AD was affecting particularly sensitive parts of the body (e.g., face).
- The location of AD, as well as AD’s effect on sleep, may be important from a quality-of-life standpoint. Two studies8,9 included sleep as a consideration in their AD health state.
- The states states used as the basis for the utility estimation varied greatly across studies. Two only studies mapped utilities to ICA scores10,11, and their methods were unclear.

CONCLUSIONS

- There are several published studies presenting utility estimates in AD. However, they vary greatly in terms of methods employed.
- Economic evaluations in AD, the results of which are sensitive to uncertainty in utility inputs, have relied on various estimates.

REFERENCES

1. Chen SC, Bayoumi AM, Soon SL, Aftergut K, Cruz P, Sexton SA, et al. A catalog of health economic evaluations in AD, the results of which are sensitive to uncertainty in utility inputs, have relied on various estimates.
2. Garside R, Stein K. A cost-utility analysis of pimecrolimus cream 1% versus topical corticosteroids in AD. Health Technology Assessment. 2006. Available at: http://www.valueofhealth.org/background. Accessed Feb 23, 2006. E-mail: dmladsi@rti.org Fax: +1.919.541.7222 Phone: +1.919.541.7094 200 Park Offices Drive RTP Health Solutions, Research Triangle Park, NC, United States

Table 5. Utility Estimates Based on Short-Form Health Surveys

<table>
<thead>
<tr>
<th>Source of utility estimates</th>
<th>Number of children</th>
<th>Standardisation</th>
<th>Measurment Technique</th>
<th>Health State</th>
<th>Utility Estimate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Garside and colleagues5</td>
<td>578</td>
<td>TTO</td>
<td>STAI</td>
<td>Severe AD</td>
<td>0.60</td>
</tr>
<tr>
<td>Ellis and colleagues3</td>
<td>53</td>
<td>TTO</td>
<td>VAS</td>
<td>Severe AD</td>
<td>0.57</td>
</tr>
<tr>
<td>Costello and colleagues15</td>
<td>41</td>
<td>TTO</td>
<td>EQ-5D</td>
<td>Severe AD</td>
<td>0.54</td>
</tr>
</tbody>
</table>

Hydrogen and colleagues2 conducted a cost-effectiveness analysis of tacrolimus ointment versus corticosteroids in patients with moderate to severe AD. Their results showed:

- The efficacy of tacrolimus and corticosteroids was not statistically different.
- The utility estimates were gathered from a US mail survey in Sweden that produced 242 responses.
- The health state described in the survey was based on the definitions of improvement included in the clinical trial. The health states, and corresponding utilities, were as follows:
  - Virtually cleared: 0.78 to 0.84 improvement from baseline.
  - Slight improvement: 0.50 to 0.56 improvement from baseline.
  - Moderate: 0.30 to 0.36 improvement from baseline.
  - Poor: 0.10 to 0.20 improvement from baseline.

Other Findings

- No studies considered whether AD was affecting particularly sensitive parts of the body (e.g., face).
- The location of AD, as well as AD’s effect on sleep, may be important from a quality-of-life standpoint. Two studies8,9 included sleep as a consideration in their AD health state.
- The states states used as the basis for the utility estimation varied greatly across studies. Two only studies mapped utilities to ICA scores10,11, and their methods were unclear.

CONCLUSIONS

- There are several published studies presenting utility estimates in AD. However, they vary greatly in terms of methods employed.
- Economic evaluations in AD, the results of which are sensitive to uncertainty in utility inputs, have relied on various estimates.

REFERENCES

1. Chen SC, Bayoumi AM, Soon SL, Aftergut K, Cruz P, Sexton SA, et al. A catalog of health economic evaluations in AD, the results of which are sensitive to uncertainty in utility inputs, have relied on various estimates.
2. Garside R, Stein K. A cost-utility analysis of pimecrolimus cream 1% versus topical corticosteroids in AD. Health Technology Assessment. 2006. Available at: http://www.valueofhealth.org/background. Accessed Feb 23, 2006. E-mail: dmladsi@rti.org Fax: +1.919.541.7222 Phone: +1.919.541.7094 200 Park Offices Drive RTP Health Solutions, Research Triangle Park, NC, United States

Table 5. Utility Estimates Based on Short-Form Health Surveys

<table>
<thead>
<tr>
<th>Source of utility estimates</th>
<th>Number of children</th>
<th>Standardisation</th>
<th>Measurment Technique</th>
<th>Health State</th>
<th>Utility Estimate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Garside and colleagues5</td>
<td>578</td>
<td>TTO</td>
<td>STAI</td>
<td>Severe AD</td>
<td>0.60</td>
</tr>
<tr>
<td>Ellis and colleagues3</td>
<td>53</td>
<td>TTO</td>
<td>VAS</td>
<td>Severe AD</td>
<td>0.57</td>
</tr>
<tr>
<td>Costello and colleagues15</td>
<td>41</td>
<td>TTO</td>
<td>EQ-5D</td>
<td>Severe AD</td>
<td>0.54</td>
</tr>
</tbody>
</table>

Hydrogen and colleagues2 conducted a cost-effectiveness analysis of tacrolimus ointment versus corticosteroids in patients with moderate to severe AD. Their results showed:

- The efficacy of tacrolimus and corticosteroids was not statistically different.
- The utility estimates were gathered from a US mail survey in Sweden that produced 242 responses.
- The health state described in the survey was based on the definitions of improvement included in the clinical trial. The health states, and corresponding utilities, were as follows:
  - Virtually cleared: 0.78 to 0.84 improvement from baseline.
  - Slight improvement: 0.50 to 0.56 improvement from baseline.
  - Moderate: 0.30 to 0.36 improvement from baseline.
  - Poor: 0.10 to 0.20 improvement from baseline.

Other Findings

- No studies considered whether AD was affecting particularly sensitive parts of the body (e.g., face).
- The location of AD, as well as AD’s effect on sleep, may be important from a quality-of-life standpoint. Two studies8,9 included sleep as a consideration in their AD health state.
- The states states used as the basis for the utility estimation varied greatly across studies. Two only studies mapped utilities to ICA scores10,11, and their methods were unclear.

CONCLUSIONS

- There are several published studies presenting utility estimates in AD. However, they vary greatly in terms of methods employed.
- Economic evaluations in AD, the results of which are sensitive to uncertainty in utility inputs, have relied on various estimates.

REFERENCES

1. Chen SC, Bayoumi AM, Soon SL, Aftergut K, Cruz P, Sexton SA, et al. A catalog of health economic evaluations in AD, the results of which are sensitive to uncertainty in utility inputs, have relied on various estimates.
2. Garside R, Stein K. A cost-utility analysis of pimecrolimus cream 1% versus topical corticosteroids in AD. Health Technology Assessment. 2006. Available at: http://www.valueofhealth.org/background. Accessed Feb 23, 2006. E-mail: dmladsi@rti.org Fax: +1.919.541.7222 Phone: +1.919.541.7094 200 Park Offices Drive RTP Health Solutions, Research Triangle Park, NC, United States